Free Trial
NASDAQ:IKNA

Ikena Oncology (IKNA) Stock Price, News & Analysis

Ikena Oncology logo
$1.70 +0.02 (+1.19%)
(As of 11/20/2024 ET)

About Ikena Oncology Stock (NASDAQ:IKNA)

Key Stats

Today's Range
$1.68
$1.70
50-Day Range
$1.66
$1.76
52-Week Range
$1.22
$2.32
Volume
15,789 shs
Average Volume
69,032 shs
Market Capitalization
$82.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00
Consensus Rating
Moderate Buy

Company Overview

Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Ikena Oncology Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
70th Percentile Overall Score

IKNA MarketRank™: 

Ikena Oncology scored higher than 70% of companies evaluated by MarketBeat, and ranked 331st out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Ikena Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Ikena Oncology has only been the subject of 2 research reports in the past 90 days.

  • Read more about Ikena Oncology's stock forecast and price target.
  • Earnings Growth

    Earnings for Ikena Oncology are expected to grow in the coming year, from ($0.91) to ($0.70) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Ikena Oncology is -1.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Ikena Oncology is -1.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Ikena Oncology has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Ikena Oncology's valuation and earnings.
  • Percentage of Shares Shorted

    0.44% of the float of Ikena Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    Ikena Oncology has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Ikena Oncology has recently decreased by 12.11%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Ikena Oncology does not currently pay a dividend.

  • Dividend Growth

    Ikena Oncology does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.44% of the float of Ikena Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    Ikena Oncology has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Ikena Oncology has recently decreased by 12.11%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Ikena Oncology has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Ikena Oncology this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Ikena Oncology insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 5.94% of the stock of Ikena Oncology is held by insiders.

  • Percentage Held by Institutions

    75.00% of the stock of Ikena Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Ikena Oncology's insider trading history.
Receive IKNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ikena Oncology and its competitors with MarketBeat's FREE daily newsletter.

IKNA Stock News Headlines

Analysts Set Expectations for Ikena Oncology FY2024 Earnings
JD Vance Predicts: Wall Street vs. Trump & Your Money
Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.
Buy Rating for Ikena Oncology Driven by Promising IK-595 Developments
Ikena Oncology Reports Strategic Realignment and Financial Performance
See More Headlines

IKNA Stock Analysis - Frequently Asked Questions

Ikena Oncology's stock was trading at $1.97 at the start of the year. Since then, IKNA stock has decreased by 13.7% and is now trading at $1.70.
View the best growth stocks for 2024 here
.

Ikena Oncology, Inc. (NASDAQ:IKNA) issued its quarterly earnings results on Thursday, November, 7th. The company reported ($0.19) earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.08.

Ikena Oncology (IKNA) raised $125 million in an initial public offering on Friday, March 26th 2021. The company issued 7,800,000 shares at $15.00-$17.00 per share. Jefferies, Cowen, Credit Suisse and William Blair acted as the underwriters for the IPO.

Ikena Oncology's top institutional shareholders include BML Capital Management LLC (1.50%), NEA Management Company LLC (1.24%), Jacobs Levy Equity Management Inc. (0.81%) and Geode Capital Management LLC (0.56%). Insiders that own company stock include Venture Fund Xi LP Atlas, Jean Francois Formela and Xiaoyan Michelle Zhang.
View institutional ownership trends
.

Shares of IKNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Ikena Oncology investors own include Waste Connections (WCN), iShares Micro-Cap ETF (IWC), The RMR Group (RMR), DiamondRock Hospitality (DRH), American Water Works (AWK), AUO (AUOTY) and Triple Flag Precious Metals (TFPM).

Company Calendar

Last Earnings
11/07/2024
Today
11/21/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
3/11/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:IKNA
Fax
N/A
Employees
70
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.00
High Stock Price Target
$4.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+76.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-68,170,000.00
Pretax Margin
-9,067.17%

Debt

Sales & Book Value

Annual Sales
$659,000.00
Book Value
$3.52 per share

Miscellaneous

Free Float
45,391,000
Market Cap
$82.04 million
Optionable
Not Optionable
Beta
0.48
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

This page (NASDAQ:IKNA) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners